Literature DB >> 24210286

Comparison between two labeled agents in mice using a coinjection-ratio approach in contrast to a conventional group approach.

Shuping Dou1, Yuzhen Wang, Bruce Barton, Ling Chen, Mary Rusckowski, Leonard D Shultz, Dale L Greiner, Guozheng Liu.   

Abstract

INTRODUCTION: The differences between two agents often need to be accurately defined in vivo. Usually they are injected respectively into two groups of subjects. However, if the two agents do not interact with each other in vivo, a coinjection would serve the same purpose. We believe some individual differences in biodistribution may be circumvented through this approach by calculating organ level ratios.
METHODS: A model system of MORF/cMORF pretargeting (MORF/cMORF is a complementary pair of DNA analogues) was employed in connection with an on-going tumor therapeutic project. Human LS174T cells were implanted into the flank of severely immuno-compromised NOD-scid IL2rg(null) mice. The tumor was confirmed to express TAG-72 antigens. At 16 days post tumor inoculation, mice received IV 60 μg of MORF-conjugated CC49 (an antiTAG-72 antibody), followed 2 days later by a low-mass-dose IV coinjection containing 2.5 μg of (90)Y-cMORF and 2.5 μg of (99m)Tc-cMORF. At 3 h post radioactivity injection, the distribution of (99m)Tc was imaged on a SPECT/CT camera and then organs were excised and counted for (90)Y and (99m)Tc. Because the two labeled cMORFs do not react or interact with each other in vivo, the two groups of (90)Y and (99m)Tc data enabled a conventional group comparison. In a new effort, (90)Y/(99m)Tc ratios were calculated. Student's t-test and retrospective power analysis were performed for both approaches. In the new approach, the ratios were set at 1 as the null hypothesis.
RESULTS: The Student's t-test in the conventional group approach indicated that the two labeled cMORFs distributed similarly, but significant differences were observed in salivary gland and large intestines. The coinjection-ratio approach certainly did not subvert the results of the conventional approach but revealed subtler differences. The P values were reduced, the powers were increased in most organs, and more significant differences were observed. The increased sensitivity was due to the reduced CV%s (SD/average*100%) of the (90)Y/(99m)Tc ratios. Therefore, some individual differences were circumvented and notably the ratio approach differentiated individual differences into ratio-correctable and ratio-uncorrectable.
CONCLUSIONS: Although the conventional approach is reliable, the coinjection-ratio approach using organ level ratios is more sensitive and therefore is recommended whenever possible. In addition, it differentiates individual differences into "coinjection correctable" and "coinjection uncorrectable".
© 2013.

Entities:  

Keywords:  Biodistribution; In vivo evaluation; Statistical analysis; Translational study; Tumor pretargeting

Mesh:

Substances:

Year:  2013        PMID: 24210286      PMCID: PMC3855254          DOI: 10.1016/j.nucmedbio.2013.10.001

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  17 in total

1.  A preclinical 188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49.

Authors:  Guozheng Liu; Shuping Dou; Stephen Baker; Ali Akalin; Dengfeng Cheng; Ling Chen; Mary Rusckowski; Donald J Hnatowich
Journal:  Cancer Biol Ther       Date:  2010-10-15       Impact factor: 4.742

2.  A comparison in monkeys of (99m)Tc labeled to a peptide by 4 methods.

Authors:  M Rusckowski; T Qu; S Gupta; A Ley; D J Hnatowich
Journal:  J Nucl Med       Date:  2001-12       Impact factor: 10.057

3.  90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy.

Authors:  Guozheng Liu; Shuping Dou; Yuxia Liu; Yuzhen Wang; Mary Rusckowski; Donald J Hnatowich
Journal:  Bioconjug Chem       Date:  2011-11-03       Impact factor: 4.774

4.  Tumor pretargeting in mice using (99m)Tc-labeled morpholino, a DNA analog.

Authors:  Guozheng Liu; Kennedy Mang'era; Ning Liu; Suresh Gupta; Mary Rusckowski; Donald J Hnatowich
Journal:  J Nucl Med       Date:  2002-03       Impact factor: 10.057

5.  Different chelators and different peptides together influence the in vitro and mouse in vivo properties of 99Tcm.

Authors:  T Qu; Y Wang; Z Zhu; M Rusckowski; D J Hnatowich
Journal:  Nucl Med Commun       Date:  2001-02       Impact factor: 1.690

6.  Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells.

Authors:  Leonard D Shultz; Bonnie L Lyons; Lisa M Burzenski; Bruce Gott; Xiaohua Chen; Stanley Chaleff; Malak Kotb; Stephen D Gillies; Marie King; Julie Mangada; Dale L Greiner; Rupert Handgretinger
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

7.  Tumor pretargeting in mice using MORF conjugated CC49 antibody and radiolabeled complimentary cMORF effector.

Authors:  G Liu; S Dou; P H Pretorius; X Liu; L Chen; M Rusckowski; D J Hnatowich
Journal:  Q J Nucl Med Mol Imaging       Date:  2009-12-15       Impact factor: 2.346

8.  Replacing 99mTc with 111In improves MORF/cMORF pretargeting by reducing intestinal accumulation.

Authors:  Guozheng Liu; Dengfeng Cheng; Shuping Dou; Xiangji Chen; Minmin Liang; P Hendrik Pretorius; Mary Rusckowski; Donald J Hnatowich
Journal:  Mol Imaging Biol       Date:  2009-03-27       Impact factor: 3.488

9.  The ratio of maximum percent tumour accumulations of the pretargeting agent and the radiolabelled effector is independent of tumour size.

Authors:  Guozheng Liu; Shuping Dou; Minmin Liang; Xiangji Chen; Mary Rusckowski; Donald J Hnatowich
Journal:  Eur J Cancer       Date:  2009-10-05       Impact factor: 9.162

10.  Rules of thumb for maximum percent tumor accumulation.

Authors:  Guozheng Liu
Journal:  Nucl Med Biol       Date:  2013-06-18       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.